Ignacio F. Mata, Ph.D.

Our Team: Ignacio F. Mata, Ph.D.
Post-doctoral Fellow

Post-doctoral fellow, University of Washington Department of Neurology.

Education/Training

2006-present: University of Washington. Seattle, WA.

2001-2006: Universidad de Oviedo. Asturias, Spain. Ph.D. (cum laude)

2004-2006: Mayo Clinic. Jacksonville, FL. Predoctoral graduate student.

2001-2003: Hospital Universitario Central de Asturias, Oviedo, Spain. Predoctoral graduate student.

1995-2001: Universidad de Oviedo. Asturias, Spain. BS.

Positions and Employment

2006- : Postdoctoral Fellowship, Department of Neurology, University of Washington, Seattle. Supervisor Dr. Cyrus Zabetian

2004-2006: Predoctoral Graduate Student, Department of Neurosciences, Mayo Clinic, Jacksonville, FL. Supervisor: Dr. Matthew Farrer

2001-2003: Research Assistant , Molecular genetics Department in Hospital Universitario Central de Asturias, SPAIN. Supervisors: Dr. E. Coto and V. Alvarez

Professional Membership

American Society of Human Genetics

Publications

1. Alvarez V, Mata IF, Gonzalez P, Lahoz CH, Martinez C, Pena J, Guisasola LM and Coto E (2002) Association between the TNFalpha-308 A/G polymorphism and the onset-age of Alzheimer disease, Am J Med Genet 114: 574-577.

2. Mata IF, Alvarez V, Garcia-Moreira V, Guisasola LM, Ribacoba R, Salvador C, Blazquez M, Sarmiento RG, Lahoz CH, Menes BB and Garcia EC (2002) Single-nucleotide polymorphisms in the promoter region of the PARKIN gene and Parkinson's disease, Neurosci Lett 329: 149-152.

3. Mata IF, Lockhart PJ and Farrer MJ (2004) Parkin genetics: one model for Parkinson's disease, Hum Mol Genet 13 Spec No 1: R127-133.

4. Huerta C, Alvarez V, Mata IF, Coto E, Ribacoba R, Martinez C, Blazquez M, Guisasola LM, Salvador C, Lahoz CH and Pena J (2004) Chemokines (RANTES and MCP-1) and chemokine-receptors (CCR2 and CCR5) gene polymorphisms in Alzheimer's and Parkinson's disease, Neurosci Lett 370: 151-154.

5. Farrer M, Stone J, Mata IF, Lincoln S, Kachergus J, Hulihan M, Strain KJ and Maraganore DM (2005) LRRK2 mutations in Parkinson disease, Neurology 65: 738-40.

6. Aasly JO, Toft M, Fernandez-Mata I, Kachergus J, Hulihan M, White LR and Farrer M (2005) Clinical features of LRRK2-associated Parkinson's disease in central Norway, Ann Neurol 57: 762-765.

7. Kachergus J*, Mata IF*, Hulihan M, Taylor JP, Lincoln S, Aasly J, Gibson JM, Ross OA, Lynch T, Wiley J, Payami H, Nutt J, Maraganore DM, Czyzewski K, Styczynska M, Wszolek ZK, Farrer MJ and Toft M (2005) Identification of a Novel LRRK2 Mutation Linked to Autosomal Dominant Parkinsonism: Evidence of a Common Founder across European Populations, Am J Hum Genet 76.

8. Toft M, Mata IF, Kachergus JM, Ross OA and Farrer MJ (2005) LRRK2 mutations and Parkinsonism, Lancet 365: 1229-1230.

9. Mata IF, Alvarez V, Coto E, Blazquez M, Guisasola LM, Salvador C, Kachergus JM, Lincoln SJ and Farrer M (2005) Homozygous partial genomic triplication of the parkin gene in early-onset parkinsonism, Neurosci Lett 380: 257-259.

10. Mata IF, Taylor JP, Kachergus J, Hulihan M, Huerta C, Lahoz C, Blazquez M, Guisasola LM, Salvador C, Ribacoba R, Martinez C, Farrer M and Alvarez V (2005) LRRK2 R1441G in Spanish patients with Parkinson's disease, Neurosci Letters 382: 309-311.

11. Gosal D, Ross OA, Wiley J, Irvine GB, Johnston JA, Toft M, Mata IF, Kachergus J, Hulihan M, Taylor JP, Lincoln SJ, Farrer MJ, Lynch T, Mark Gibson J (2005) Clinical traits of LRRK2-associated Parkinson's disease in Ireland: A link between familial and idiopathic PD. Parkinsonism Relat Disord 11: 349-52.

12. Mata IF, Kachergus JM, Taylor JP, Lincoln S, Aasly J, Lynch T, Hulihan MM, Cobb SA, Wu RM, Lu CS, Lahoz C, Wszolek ZK,Farrer MJ (2005) Lrrk2 pathogenic substitutions in Parkinson's disease. Neurogenetics: 1-7.

13. Mata IF, Ross OA, Kachergus J, Huerta C, Ribacoba R, Moris G, Blazquez M, Guisasola LM, Salvador C, Martinez C, Farrer M,Alvarez V (2005) LRRK2 mutations are a common cause of Parkinson's disease in Spain. European Journal of Neurology,13:391-394.

14. Mata IF, Bodkin CL, Adler CH, Lin S-C, Uitti RJ, Farrer MJ,Wszolek ZK (2005) Genetics of restless legs syndrome- A review. Parkinsonism Relat Disord 12: 1-7.

15. Taylor JP, Mata IF, Farrer MJ (2006) LRRK2: a common pathway for parkinsonism, pathogenesis and prevention? Trends Mol Med. 12: 76-82

16. Mata IF, Wedemeyer WJ, Farrer MJ, Taylor JP, Gallo KA (2006) LRRK2 in Parkinson's disease: protein domains and functional insights. Trends Neuroscience. 29: 286-93

17. Dachsel JC, Mata IF, Ross OA, Taylor JP, Lincoln SJ, Hinkle KM, Huerta C, Ribacoba R, Blazquez M, Alvarez V and Farrer MJ (2006) Digenic parkinsonism: Investigation of the synergistic effects of PRKN and LRRK2, Neurosci Lett, 410:80-4.

18. Dachsel, JC, Ross, OA, Mata, IF, Kachergus, J, Toft, M, Cannon, A, Baker, M, Adamson, J, Hutton, M, Dickson, DW and Farrer, MJ (2006) Lrrk2 G2019S substitution in frontotemporal lobar degeneration with ubiquitin-immunoreactive neuronal inclusions, Acta Neuropathol (Berl) epub.

19. Toft M, Mata IF, Ross OA, Kachergus J, Hulihan MM, Haugarvoll K, et al.: Pathogenicity of the Lrrk2 R1514Q substitution in Parkinson's disease (2007). Mov Disord epub